Fresenius reports another strong quarter and confirms guidance
. Q3/2017: - Sales €8.3 billion (+12%, +15% in constant currency) - EBIT1 €1,129 million (+5%, +9% in constant currency…
. Q3/2017: - Sales €8.3 billion (+12%, +15% in constant currency) - EBIT1 €1,129 million (+5%, +9% in constant currency…
Prior to today's regular Supervisory Board meeting of Deutsche Lufthansa AG, Wolfgang Mayrhuber, Chairman of the Supervi…
Fresenius Kabi has successfully closed the acquisition of Merck KGaA’s biosimilars business. The transaction comprises t…
Fresenius expects new record sales and earnings in the current business year. At the Annual General Meeting in Frankfurt…
Merck, a leading science and technology company, today announced that Constantin Birnstiel (45) will become Head of Grou…
- Transactions provide access to attractive pharmaceutical growth markets - Acquisition of Akorn, Inc. expected to be ac…
This year’s European Business Conference for Pharma and Biotech (EBDC) took place 27 and 28 September in Offenbach, a ci…
With the strategic initiative ONE Global Headquarters, Merck is continuing the development of its main site in Darmstadt…
ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromis…
More than 100 business developers and other decision makers from the pharmaceutical and biotechnology industry and inves…